Want to see NRSN full AI Analyst Report?
NRSN Stock Chart & Stats
$0.71
-$0.07(-5.66%)
At close: 4:00 PM EST
$0.71
-$0.07(-5.66%)
Day’s Range― - ―
52-Week Range$0.63 - $2.18
Previous CloseN/A
Volume34.16K
Average Volume (3M)944.42K
Market Cap
$25.05M
Enterprise Value$17.39M
Total Cash (Recent Filing)$166.00K
Total Debt (Recent Filing)$170.00K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Sep 02, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding35,349,810
10 Day Avg. Volume256,142
30 Day Avg. Volume944,423
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-12.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.55
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.57
Forecast
1Y Price Target
$6.00Price Target Upside745.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$714.07K
Bulls Say, Bears Say
Bulls Say
ManufacturingNRSN has completed the scale-up of its manufacturing process of PrimeC to commercial scale.
Product DevelopmentNeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS), and previously received feedback from the FDA regarding the Phase trial 3 design for PrimeC.
Bears Say
Financial ConstraintsWhile the data previously generated for PrimeC has been promising, the company still has capital constraints, including its 'baby shelf' limitations, which will make it difficult to raise sufficient capital to fully finance the Phase 3 trial.
Funding UncertaintyNeuroSense still has not signed a definitive agreement with the previously-undisclosed partner to fund PrimeC’s Phase 3 program and commercialization.
Regulatory ChallengesThe company received negative feedback from Health Canada regarding an accelerated approval pathway for PrimeC for treating ALS.
Neurosense Therapeutics Ltd. News
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.63 and its highest was $2.18 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Neurosense Therapeutics Ltd.’s market cap is $25.05M.
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 54 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Mar 31, 2026. The company reported -$0.235 earnings per share for the quarter, missing the consensus estimate of -$0.085 by -$0.15.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -0.21.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 35,349,810 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.235 in its last earnings report, missing expectations of -$0.085. Following the earnings report the stock price went up 3.283%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
NRSN Stock 12 Month Forecast
Average Price Target
$6.00
▲(745.07% Upside)
Technical Analysis
Ownership Overview
19.88% Insiders
0.04% Mutual Funds
0.33% Other Institutional Investors
79.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---